A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Chunyin, Cao, Xiaodan, Wang, Zongda, Hu, Xue, Yao, Yanfeng, Zhou, Yiwu, Liu, Peipei, Liu, Xiaowu, Gao, Ge, Hu, Xiao, Zhang, Yecheng, Chen, Zhen, Gao, Li, Peng, Yun, Jia, Fangfang, Shan, Chao, Yu, Li, Liu, Kunpeng, Li, Nan, Guo, Weiwei, Jiang, Guoping, Min, Juan, Zhang, Jianjian, Yang, Lu, Shi, Meng, Hou, Tianquan, Li, Yanan, Liang, Weichen, Lu, Guoqiao, Yang, Congyi, Wang, Yuting, Xia, Kaiwen, Xiao, Zheng, Xue, Jianhua, Huang, Xueyi, Chen, Xin, Ma, Haixia, Song, Donglin, Pan, Zhongzong, Wang, Xueping, Guo, Haibing, Liang, Hong, Yuan, Zhiming, Guan, Wuxiang, Deng, Su-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189090/
https://www.ncbi.nlm.nih.gov/pubmed/34097570
http://dx.doi.org/10.1080/19420862.2021.1930636
_version_ 1783705445215502336
author Gu, Chunyin
Cao, Xiaodan
Wang, Zongda
Hu, Xue
Yao, Yanfeng
Zhou, Yiwu
Liu, Peipei
Liu, Xiaowu
Gao, Ge
Hu, Xiao
Zhang, Yecheng
Chen, Zhen
Gao, Li
Peng, Yun
Jia, Fangfang
Shan, Chao
Yu, Li
Liu, Kunpeng
Li, Nan
Guo, Weiwei
Jiang, Guoping
Min, Juan
Zhang, Jianjian
Yang, Lu
Shi, Meng
Hou, Tianquan
Li, Yanan
Liang, Weichen
Lu, Guoqiao
Yang, Congyi
Wang, Yuting
Xia, Kaiwen
Xiao, Zheng
Xue, Jianhua
Huang, Xueyi
Chen, Xin
Ma, Haixia
Song, Donglin
Pan, Zhongzong
Wang, Xueping
Guo, Haibing
Liang, Hong
Yuan, Zhiming
Guan, Wuxiang
Deng, Su-Jun
author_facet Gu, Chunyin
Cao, Xiaodan
Wang, Zongda
Hu, Xue
Yao, Yanfeng
Zhou, Yiwu
Liu, Peipei
Liu, Xiaowu
Gao, Ge
Hu, Xiao
Zhang, Yecheng
Chen, Zhen
Gao, Li
Peng, Yun
Jia, Fangfang
Shan, Chao
Yu, Li
Liu, Kunpeng
Li, Nan
Guo, Weiwei
Jiang, Guoping
Min, Juan
Zhang, Jianjian
Yang, Lu
Shi, Meng
Hou, Tianquan
Li, Yanan
Liang, Weichen
Lu, Guoqiao
Yang, Congyi
Wang, Yuting
Xia, Kaiwen
Xiao, Zheng
Xue, Jianhua
Huang, Xueyi
Chen, Xin
Ma, Haixia
Song, Donglin
Pan, Zhongzong
Wang, Xueping
Guo, Haibing
Liang, Hong
Yuan, Zhiming
Guan, Wuxiang
Deng, Su-Jun
author_sort Gu, Chunyin
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
format Online
Article
Text
id pubmed-8189090
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81890902021-06-17 A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351 Gu, Chunyin Cao, Xiaodan Wang, Zongda Hu, Xue Yao, Yanfeng Zhou, Yiwu Liu, Peipei Liu, Xiaowu Gao, Ge Hu, Xiao Zhang, Yecheng Chen, Zhen Gao, Li Peng, Yun Jia, Fangfang Shan, Chao Yu, Li Liu, Kunpeng Li, Nan Guo, Weiwei Jiang, Guoping Min, Juan Zhang, Jianjian Yang, Lu Shi, Meng Hou, Tianquan Li, Yanan Liang, Weichen Lu, Guoqiao Yang, Congyi Wang, Yuting Xia, Kaiwen Xiao, Zheng Xue, Jianhua Huang, Xueyi Chen, Xin Ma, Haixia Song, Donglin Pan, Zhongzong Wang, Xueping Guo, Haibing Liang, Hong Yuan, Zhiming Guan, Wuxiang Deng, Su-Jun MAbs Reports Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic. Taylor & Francis 2021-06-07 /pmc/articles/PMC8189090/ /pubmed/34097570 http://dx.doi.org/10.1080/19420862.2021.1930636 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reports
Gu, Chunyin
Cao, Xiaodan
Wang, Zongda
Hu, Xue
Yao, Yanfeng
Zhou, Yiwu
Liu, Peipei
Liu, Xiaowu
Gao, Ge
Hu, Xiao
Zhang, Yecheng
Chen, Zhen
Gao, Li
Peng, Yun
Jia, Fangfang
Shan, Chao
Yu, Li
Liu, Kunpeng
Li, Nan
Guo, Weiwei
Jiang, Guoping
Min, Juan
Zhang, Jianjian
Yang, Lu
Shi, Meng
Hou, Tianquan
Li, Yanan
Liang, Weichen
Lu, Guoqiao
Yang, Congyi
Wang, Yuting
Xia, Kaiwen
Xiao, Zheng
Xue, Jianhua
Huang, Xueyi
Chen, Xin
Ma, Haixia
Song, Donglin
Pan, Zhongzong
Wang, Xueping
Guo, Haibing
Liang, Hong
Yuan, Zhiming
Guan, Wuxiang
Deng, Su-Jun
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title_full A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title_fullStr A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title_full_unstemmed A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title_short A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
title_sort human antibody of potent efficacy against sars-cov-2 in rhesus macaques showed strong blocking activity to b.1.351
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189090/
https://www.ncbi.nlm.nih.gov/pubmed/34097570
http://dx.doi.org/10.1080/19420862.2021.1930636
work_keys_str_mv AT guchunyin ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT caoxiaodan ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangzongda ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huxue ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yaoyanfeng ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhouyiwu ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liupeipei ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liuxiaowu ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT gaoge ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huxiao ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhangyecheng ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT chenzhen ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT gaoli ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT pengyun ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT jiafangfang ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT shanchao ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yuli ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liukunpeng ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT linan ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guoweiwei ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT jiangguoping ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT minjuan ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhangjianjian ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yanglu ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT shimeng ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT houtianquan ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liyanan ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liangweichen ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT luguoqiao ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yangcongyi ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangyuting ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xiakaiwen ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xiaozheng ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xuejianhua ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huangxueyi ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT chenxin ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT mahaixia ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT songdonglin ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT panzhongzong ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangxueping ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guohaibing ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT lianghong ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yuanzhiming ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guanwuxiang ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT dengsujun ahumanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guchunyin humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT caoxiaodan humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangzongda humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huxue humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yaoyanfeng humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhouyiwu humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liupeipei humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liuxiaowu humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT gaoge humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huxiao humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhangyecheng humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT chenzhen humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT gaoli humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT pengyun humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT jiafangfang humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT shanchao humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yuli humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liukunpeng humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT linan humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guoweiwei humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT jiangguoping humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT minjuan humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT zhangjianjian humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yanglu humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT shimeng humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT houtianquan humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liyanan humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT liangweichen humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT luguoqiao humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yangcongyi humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangyuting humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xiakaiwen humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xiaozheng humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT xuejianhua humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT huangxueyi humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT chenxin humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT mahaixia humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT songdonglin humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT panzhongzong humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT wangxueping humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guohaibing humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT lianghong humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT yuanzhiming humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT guanwuxiang humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351
AT dengsujun humanantibodyofpotentefficacyagainstsarscov2inrhesusmacaquesshowedstrongblockingactivitytob1351

Ejemplares similares